

Insulin Resistance in Women with Polycystic Ovary Syndrome: Optimising treatment by Implementing an in vitro Insulin Resistance Organ Culture Model

Sandhu, H & Kuburas, R

Published PDF deposited in Coventry University's Repository

Original citation:

Sandhu, H & Kuburas, R 2015, 'Insulin Resistance in Women with Polycystic Ovary Syndrome: Optimising treatment by Implementing an in vitro Insulin Resistance Organ Culture Model' *Clinics in Mother and Child Health*, vol 12, no. 2, 1000e107 <https://dx.doi.org/10.4172/2090-7214.1000e107>

DOI 10.4172/2090-7214.1000e107

ISSN 2090-7214

Publisher: OMICS International

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Copyright © and Moral Rights are retained by the author(s) and/ or other copyright owners. A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. This item cannot be reproduced or quoted extensively from without first obtaining permission in writing from the copyright holder(s). The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the copyright holders.

Insulin Resistance in Women with Polycystic Ovary Syndrome: Optimising treatment by Implementing an *in vitro* Insulin Resistance Organ Culture Model

Sandhu H^{*} and Kuburas R

Faculty Research Centre in Applied Biological and Exercise Sciences, Faculty of Health & Life Sciences, Coventry University, UK

***Corresponding author:** Dr Hardip Sandhu, Faculty Research Centre in Applied Biological and Exercise Sciences, Faculty of Health & Life Sciences, Coventry University, UK, Tel: +44(0)2477659305; E-mail: hardip.sandhu@coventry.ac.uk

Received date: June 15, 2015; **Accepted date:** June 16, 2015; **Published date:** June 22, 2015

Copyright: © 2015 Sandhu H. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Editorial

Polycystic ovary syndrome (PCOS) affects about 5-10% of fertile women and is characterised by insulin resistance (IR), dyslipidaemia, hyperandrogenism, and oligomenorrhoe. The metabolic disruption in PCOS women requires treatment to prevent the progression of IR to diabetes and cardiovascular disease. Metformin is currently first line treatment for metabolic/glycemic abnormalities, but lacks beneficial effect on IR PCOS patients with side-effects and cost outweighing benefits. Rosiglitazone has shown to reduce IR, but it was recently withdrawn from the market due to severe side-effects. Basic research into developing optimised drug treatments for IR in PCOS is critical to reducing the development of PCOS associated diabetes and cardiovascular disease. Testing and optimising drugs to reduce IR in PCOS patient samples is difficult due to ethical restrictions. *In vitro* organ culture models are valuable and reliable. Coronary arteries incubated with high doses of insulin and glucose will be screened for reliable intracellular IR associated biomarkers by western blot and real time PCR analysis. Vascular function by wire-myograph analysis will validate endothelial dysfunction and assess myocardial vascular injury associated responses. The associated response to clinically relevant anti-diabetic treatment options and adjunct therapy will be investigated. Developing a PCOS IR simulated organ culture model will enable us to understand the complicated intracellular signalling mechanisms leading to IR and may lead to development of potential new drug therapy options improving the PCOS IR treatment outcome.

Keywords: Polycystic ovary syndrome; Insulin resistance; Cardiovascular diseases; Insulin resistance organ culture model; Insulin resistance therapy optimisation

Introduction and Epidemiology

The key features of PCOS is (i) dysfunctional insulin activity in muscle, liver and adipose tissues leading to IR and hyperinsulinaemia and (ii) intact insulin induced overproduction of androgens by theca cells in the ovarian tissue causing hyperandrogenaemia. PCOS is a common endocrinopathy of complex etiology that produces symptoms in about 5-10% of women during their reproductive years [1].

Symptoms

The main symptoms of PCOS are anovulation, insulin resistance, and hyperandrogenaemia.

Anovulation

Anovulation results in irregular menstrual pattern (e.g. oligomenorrhoea or amenorrhoea) and infertility. The number of primordial follicles is normal in women with PCOS, while primary and secondary follicles are significantly increased. Anovulation occurs because of the lack of development of a dominant follicle [2,3]. The disturbance in menstrual pattern is so common that about 85-90% of women with oligomenorrhoea have been linked to PCOS, while 30-40% of women with amenorrhoea have PCOS [4]. Anovulatory infertility affects about 40% of women with PCOS and approximately 90-95% of anovulatory women seeking help from infertility clinics have PCOS [2].

Insulin resistance

Researchers are still trying to unravel the fundamental defects that initiate PCOS. Studies during the recent years have revealed intracellular defective mechanisms that initiate IR. In brief, insulin binds to the insulin receptor of the muscle, liver and adipose tissue cells, but is unable to trigger the downstream intracellular pathway. Dysfunctional insulin pathways in PCOS include impaired (i) autophosphorylation of tyrosine residues on the β subunit of insulin receptor and (ii) reduced phosphorylation and activation of phosphoinositide-3 kinase (PI3K), which leads to a reduced (a) phosphorylation and activation of protein kinase B (PKB), (b) phosphorylation and inactivation of glycogen synthase kinase-3 resulting in glycogen-synthase activation and (c) translocation of insulin-responsive glucose transporter-4 to the cell surface [5]. Hyperinsulinemia is found in about 80% of obese and 30-40% of lean women with PCOS [6].

Hyperandrogenaemia

High levels of male hormones create hormonal imbalance and lead to hirsutism and acne, and in some cases hypermenorrhoea. Hirsutism and acne features may be explained by difference in expression of 5 α -reductase in the sebaceous gland and the hair follicle and resulting higher dihydrotestosterone in the hair follicle [7]. In spite of IR at peripheral sites the ovary remains sensitive to insulin as observed in PCOS women with both normal and high BMI [8-10]. The action of insulin on the liver leads to a decrease in the production of sex hormone binding globulin and insulin-like growth factor 1 binding protein which results in an increase in unbound testosterone. Thus, although the ovary is the major site of increased androgen production in PCOS, IR itself may contribute to the overall androgen levels. In a study by Azziz et. al. 2004 the clinical features of PCOS women with androgen excess were hirsutism in 75.5% and acne in 14.2% [11].

Diagnosis

Clinical assessment of PCOS involves (i) history-taking of the patient with emphasis on menstrual pattern, acne, male hair growth, breast development, obesity and occurrence/history of PCOS in near family, (ii) gynecologic ultrasonography establishing "follicular arrest" and (iii) blood tests determining the serum levels of androgens.

In 2003 a consensus workshop sponsored by the European Society for Human Reproduction and Embryology and the American Society for Reproductive Medicine in Rotterdam amended the National Institutes of Health and National Institute of Child and Human Development consensus criteria to include polycystic ovaries as a third diagnostic marker and to allow for a diagnosis of PCOS if two of three criteria are met after excluding other androgen excess or related disorders, such as pituitary and adrenal dysfunction: (i) oligoovulation and/or anovulation, (ii) excess androgen activity and (iii) gynecologic ultrasound showing polycystic ovaries [12].

PCOS associated cardiovascular disease development

IR leads to endothelial- and mitochondrial- dysfunction [13], and this may lead to development of cardiovascular diseases, such as coronary atherosclerosis and coronary artery disease. A study by Dahlgren et al. showed an increased relative risk of 7.4 of developing myocardial infarction in PCOS women compared to age-matched female subjects [14]. Furthermore, activation of PI3K and PKB signalling pathways have been shown to be important risk salvage proteins in cardiovascular diseases [15], thus emphasising the role and importance of these key kinases in both IR and cardiovascular diseases.

PCOS therapy options

Management of clinical manifestations of PCOS for (i) menstrual irregularities and hirsutism includes oral contraceptives, (ii) androgen excess includes spironolactone and finasteride and (iii) infertility include clomiphene, laparoscopic ovarian drilling, gonadotropins, and assisted reproductive technology.

It is estimated that 10-20% of women with PCOS develop diabetes [16]. The effect of these drugs on reducing the IR by increasing the glucose uptake and reducing hyperandrogenaemia are not optimal, as the drugs with limited adverse effect (e.g metformin and chlomiphene) only show limited improvement in insulin sensitivity, while drugs with strong recovery of insulin sensitivity (e.g. rosiglitazone and troglitazone) have demonstrated severe adverse effects (e.g. liver failure and heart attack), and have therefore been withdrawn from the market [17]. The intracellular mechanisms involved in the manifestation of PCOS are slowly emerging including many of the physiological and cellular aspects of PCOS, however, there is a severe lack of understanding and subsequent studies designed to find optimal and specific treatment for women with PCOS and IR.

In vitro insulin resistance organ culture model

There are limits and obstacles when investigating the underlying signalling pathways of PCOS in patients, as the samples are difficult to access due to ethical restrains and the number of samples is limited. The use of relevant diabetic animal models is also problematic, as these animals suffer extremely due to their condition. Therefore, it is fundamental to develop a reliable, reproducible and easily modified model that mimics the intracellular mechanisms of PCOS IR

condition. This IR organ culture model will make it possible to investigate pathways and therapeutic influence in great detail. Previous studies have shown that addition of the key risk factors for IR (high dose of insulin and glucose) to foetal rat liver and lung tissue produces a marked alteration of the underlying key cellular components involved in IR, such as glycogen synthase activity and glycogen production. These cellular alterations are observed in PCOS women and diabetic patients as well [5,18,19]. Developing an IR organ culture model in rat coronary arteries will allow investigation of altered expression of intracellular key components observed during IR and vascular (dys)function and the associated response to clinically relevant anti-diabetic treatment options and adjunct therapy. Vascular and endothelium (dys)function can be measured by wire-myograph experiments, while intracellular key components can be studied by western blot, immunohistochemistry and mRNA and microRNA real time PCR analysis (Figure 1).




Figure 1: Overview of proposed insulin resistance organ culture model study. Left anterior descending artery segments from female sprague dawley rats will be incubated in organ culture with specific high dose of insulin and glucose, with and without clinically relevant anti-diabetic treatment options and adjunct therapy. Wire-myograph system will be used for functional studies of the vessels, while western blot and real time PCR analysis will be used for in depth molecular biology studies of key intracellular pathway components.

In addition to the IR perspective this IR organ culture model will also allow the assessment of myocardial injury or cardioprotection by measuring specific biomarkers of myocardial injury [20] and the vascular tone altered through differential expression of specific G-protein coupled receptors involved in myocardial injury development [21].

Conclusion

Development of an IR organ culture model will optimise insulin sensitivity therapy options in PCOS. The model will inform the advancement of new therapy options or modulate existing treatments with adjunct therapy, which will improve long-term outcome and life quality of women with IR due to PCOS.

References

1. Dunaif A (1997) Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. *Endocr Rev* 18: 774-800.
2. Teede H, Deeks A, Moran L (2010) Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. *BMC Med* 8: 41.

3. Brassard M, AinMelk Y, Baillargeon JP (2008) Basic infertility including polycystic ovary syndrome. *Med Clin North Am* 92: 1163-1192.
4. Carmina E, Lobo RA (1999) Do hyperandrogenic women with normal menses have polycystic ovary syndrome? *Fertil Steril* 71: 319-322.
5. Diamanti-Kandarakis E, Papavassiliou AG (2006) Molecular mechanisms of insulin resistance in polycystic ovary syndrome. *Trends Mol Med* 12: 324-332.
6. Dunaif A, Segal KR, Futterweit W, Dobrjansky A (1989) Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. *Diabetes* 38: 1165-1174.
7. Lowenstein EJ (2006) Diagnosis and management of the dermatologic manifestations of the polycystic ovary syndrome. *Dermatol Ther* 19: 210-223.
8. Bergh C, Carlsson B, Olsson JH, Selleskog U, Hillensjo T (1993) Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin. *Fertil Steril* 59: 323-331.
9. Willis D, Franks S (1995) Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the insulin receptor and not the type-I insulin-like growth factor receptor. *J Clin Endocrinol Metab* 80: 3788-3790.
10. Plymate SR, Fariss BL, Bassett ML, Matej L (1981) Obesity and its role in polycystic ovary syndrome. *J Clin Endocrinol Metab* 52: 1246-1248.
11. Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, et al. (2004) Androgen excess in women: experience with over 1000 consecutive patients. *J Clin Endocrinol Metab* 89: 453-462.
12. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). *Hum Reprod* 19: 41-47.
13. Victor VM, Rocha M, Banuls C, Alvarez A, de Pablo C, et al. (2011) Induction of oxidative stress and human leukocyte/endothelial cell interactions in polycystic ovary syndrome patients with insulin resistance. *J Clin Endocrinol Metab* 96: 3115-3122.
14. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A (1992) Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. *Acta Obstet Gynecol Scand* 71: 599-604.
15. Hausenloy DJ, Yellon DM (2004) New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. *Cardiovasc Res* 61: 448-460.
16. Tim Kenny (2013) Polycystic Ovary Syndrome. Document ID 4585, version 4.1.
17. Radosh L (2009). Drug treatments for polycystic ovary syndrome. *Am Fam Physician* 79: 671-676.
18. Eisen HJ, Glinsmann WH, Sherline P (1973) Effect of insulin on glycogen synthesis in fetal rat liver in organ culture. *Endocrinolog* 92: 584-588.
19. Gross I, Smith GJ, Wilson CM, Maniscalco WM, Ingleson LD, et al. (1980) The influence of hormones on the biochemical development of fetal rat lung in organ culture. II. *Insulin Pediatr Res* 14: 834-838.
20. Sandhu H, Maddock H (2014) Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury. *Clin Sci (Lond)* 126: 377-400.
21. Sandhu H, Ansar S, Edvinsson L (2010) Comparison of MEK/ERK pathway inhibitors on the upregulation of vascular G-protein coupled receptors in rat cerebral arteries. *Eur J Pharmacol* 644: 128-137.

This article was originally published in a special issue, entitled: "**Fertility Issues During Pregnancy**", Edited by Sandhu H